rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Srinivas Akkaraju

Director

Company insider

Files Form 4 as: Director, Alumis; Director and 10% owner, vTv Therapeutics; Director and 10% owner, Scholar Rock Holding; Director and 10% owner, Kalaris Therapeutics; Director and 10% owner, Mineralys Therapeutics; 10% owner, Neurogene; Director, Syros Pharmaceuticals; 10% owner, CARGO Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
536
Buys
71
Sells
33
Bought
$269.6M
Sold
$108.5M
Companies
20
Companies where not an officer
20
First trade
15 Feb 2005
Last trade
8 Sep 2026
Last filed
9 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
ALMS AlumisDirector · Biotechnology · last 8 Sep 202618 buys · 1 sell
VTVT vTv TherapeuticsDirector, 10% owner · Biotechnology · last 26 Jun 20260 buys · 0 sells
SRRK Scholar Rock HoldingDirector, 10% owner · Biotechnology · last 4 Jun 20264 buys · 1 sell
KLRS Kalaris TherapeuticsDirector, 10% owner · Biotechnology · last 3 Jun 20262 buys · 0 sells
MLYS Mineralys TherapeuticsDirector, 10% owner · Biotechnology · last 19 Feb 20263 buys · 0 sells
NGNE Neurogene10% owner · Biotechnology · last 26 Nov 20241 buy · 0 sells
Syros PharmaceuticalsDirector · last 16 Sep 20246 buys · 6 sells
CARGO Therapeutics10% owner · last 14 Nov 20231 buy · 0 sells
Intercept PharmaceuticalsDirector · last 8 Nov 20238 buys · 3 sells
Chinook TherapeuticsDirector · last 11 Aug 20233 buys · 0 sells
LENZ LENZ Therapeutics10% owner · Biotechnology · last 12 Apr 202211 buys · 0 sells
Jiya AcquisitionDirector, 10% owner · last 23 Sep 20210 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
07Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
8 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Sold$507K48,066 at $10.55filing
8 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Sold$507K48,065 at $10.55filing
8 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Bought$2.9M273,291 at $10.63filing
8 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Bought$2.9M273,290 at $10.63filing
8 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Sold$507K48,066 at $10.55filing
8 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Sold$507K48,065 at $10.55filing
8 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Bought$2.9M273,291 at $10.63filing
8 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Bought$2.9M273,290 at $10.63filing
4 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Bought$2.5M220,070 at $11.17filing
4 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Bought$2.5M220,070 at $11.17filing
4 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Bought$2.5M220,070 at $11.17filing
4 Sep 2026filed 9 Sep 2026ALMS AlumisBiotechnologySEC FORM 4 Bought$2.5M220,070 at $11.17filing
30 Jun 2026filed 2 Jul 2026ALMS AlumisBiotechnologySEC FORM 4 Code A—3,553 at $0.00filing
30 Jun 2026filed 2 Jul 2026ALMS Alumisoption or derivative · BiotechnologySEC FORM 4 Code A—15,528 at $0.00filing
30 Jun 2026filed 2 Jul 2026ALMS Alumisoption or derivative · BiotechnologySEC FORM 4 Code A—15,528 at $0.00filing
30 Jun 2026filed 2 Jul 2026ALMS AlumisBiotechnologySEC FORM 4 Code A—3,553 at $0.00filing
26 Jun 2026filed 29 Jun 2026VTVT vTv Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A$210K6,000 at $35.08filing
26 Jun 2026filed 29 Jun 2026VTVT vTv Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A$210K6,000 at $35.08filing
4 Jun 2026filed 8 Jun 2026SRRK Scholar Rock HoldingBiotechnologySEC FORM 4 Code A—6,839 at $0.00filing
4 Jun 2026filed 8 Jun 2026SRRK Scholar Rock Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—4,310 at $0.00filing

The newest 500 lines are listed; the numbers count every line.

News

Srinivas Akkaraju Purchases 440,140 Shares of Alumis (NASDAQ:ALMS) Stockthemarketsdaily.com · 10 Sep 2026WAVE Life Sciences (NASDAQ:WVE) and Alumis (NASDAQ:ALMS) Head to Head ComparisonALMS · dailypolitical.com · 18 Oct 2026

1 headline in the last 90 days name Srinivas Akkaraju; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.

Sectors

Health Care42
Not placed62

Buys in green, sells in red, by the company’s sector.

Related people

Lonnel CoatsDirector · Director at Mineralys Therapeutics, filing Form 4 there in the last year
Kristine PetersonDirector · Director at Mineralys Therapeutics, filing Form 4 there in the last year
Jon CongletonChief Executive Officer · Chief Executive Officer at Mineralys Therapeutics, filing Form 4 there in the last year
Keith WoodsChief Operating Officer · Chief Operating Officer at Scholar Rock Holding, filing Form 4 there in the last year
Brian Taylor SlingsbyDirector · Director at Mineralys Therapeutics, filing Form 4 there in the last year
Eric WarrenChief Commercial Officer · Also traded MLYS in the last 90 days
Daphne KarydasDirector · Also traded MLYS in the last 90 days
David Malcom RodmanChief Medical Officer · Also traded MLYS in the last 90 days